Vera Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $215.3M | $126.2M | $78.2M | $69.0M | $22.5M |
| Operating expenses | $315.5M | $167.2M | $102.0M | $90.9M | $34.4M |
| Operating income | -$315.5M | -$167.2M | -$102.0M | -$90.9M | -$34.4M |
| Interest expense | $7.5M | $7.6M | $3.8M | $992,000 | $20,000 |
| Pretax income | -$299.6M | -$152.1M | -$96.0M | -$89.1M | -$32.6M |
| Income tax expense | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 |
| Net income | -$299.6M | -$152.1M | -$96.0M | -$89.1M | -$32.6M |
| Balance Sheet | |||||
| Cash and equivalents | $354.7M | $92.6M | $45.7M | $43.5M | $79.7M |
| Current assets | $728.9M | $651.2M | $172.0M | $125.7M | $82.5M |
| Total assets | $734.7M | $655.7M | $175.5M | $131.4M | $83.7M |
| Current liabilities | $53.5M | $25.4M | $22.3M | $25.6M | $7.7M |
| Total liabilities | $130.2M | $78.5M | $73.9M | $54.5M | $14.2M |
| Total debt | $75.0M | $50.0M | $50.0M | $25.0M | $5.0M |
| Stockholders' equity | $604.5M | $577.2M | $101.7M | $76.9M | $69.6M |
| Cash Flow Statement | |||||
| Cash from operations | -$241.1M | -$134.7M | -$92.2M | -$67.6M | -$23.7M |
| Depreciation and amortization | $468,000 | $105,000 | $21,000 | $846,000 | $176,000 |
| Stock-based compensation | $37.9M | $20.8M | $11.5M | $8.9M | $3.0M |
| Capital expenditure | $630,000 | $972,000 | $63,000 | $62,000 | $0 |
| Free cash flow | -$241.7M | -$135.7M | -$92.2M | -$67.7M | -$23.7M |
| Share repurchases | $0 | $13,000 | $0 | — | — |
| Impairments | $0 | $0 | $0 | — | — |
Shares outstanding 71.8M · Free float 59.7%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.